Progress in Multiple Myeloma
Are Multiple Myeloma Patients Getting the Treatments They Need?
Some are, some aren鈥檛. Although advances in treating multiple myeloma have increased survival rates, a study from the Cleveland Clinic reports that factors such as race, insurance type, and treatment facility affect who gets recommended treatments.
The Great Smoldering Myeloma Debate: Observe or Intervene?
A retrospective study examines the myeloma-defining events and clinical presentations leading to a multiple myeloma (MM) diagnosis in a group of patients with smoldering MM.
Multiple Myeloma Treatment Tolerability: Ask the Patients
Is it possible that the answer to a single question asked of patients starting treatment for newly diagnosed multiple myeloma will identify those who may discontinue treatment because of adverse events?
Myeloma Diagnostic Tool Introduced for Primary Care Settings
Myeloma is the cancer with the worst delayed diagnosis rate. The Myeloma Diagnostic Tool was created to guide primary care providers regarding when to consider and how to evaluate a patient with suspected myeloma.
For Multiple Myeloma Patients After ASCT, Nonclinical Factors Matter, Too
Race, socioeconomic status, household composition, type of available housing and transportation. All of these factors, and more, determine how well patients with multiple myeloma do after autologous stem cell transplant.
.jpg)
Multiple Myeloma Treatment in Black and White Patients: It鈥檚 Different
Multiple myeloma treatment is becoming less common during the first year after diagnosis for non-Hispanic Black patients compared with non-Hispanic White patients. A new study examines the consequences of these delays.
In Patients with Multiple Myeloma Undergoing HCT, Can Clonal Hematopoisis Predict CVD Risk?
Clonal hematopoiesis of indeterminate potential is a possible biomarker of CVD risk in patients with multiple myeloma who are undergoing hematopoietic cell transplant.
In Multiple Myeloma, Does Obesity Affect Outcomes?
A secondary analysis of the STaMINA (BMT CTN 0702) Trial found no significant association between waist-to-hip ratio or BMI and either progression-free survival or overall survival in patients with multiple myeloma undergoing hematopoietic cell transplant.